For General Information, page-3010

I cant see anything wrong with your reasoning. If another party finds another use for ATL1102 now, they can claim the IP for that use.

Having said that, ANP have really narrowed that available field, by focusing on biomarkers and method of use against them. They have honed in on how this drug works, identified the target proteins and interaction, and have IP covering that. This relates to multiple diseases from AML, MS and lots of other inflammation disease.

So for another company to lock in asthma, for example, they would need to prove that the drug targeting the biomarkers ANP hold the IP for isnt the reason it works for Asthma. This is why I think the IP from mid 2022 is so important.

Any company could ask ANP for a licence to use the drug against asthma, targeting the biomarkers ANP hold the IP for.

You have highlighted an important thing here Boomy, and you have been all over this point for a few years. As you have said, its of great interest now, as it directly effects the ANP revenue potential, in a good way. Without IP over the nuts and bolts of how ATL1102 works, it would be open market for any drug development company to use in any indication not already named and protected.